Alzamend Neuro Inc (ALZN) Financials
ALZN Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| July 31, 2026 | 8.5 million | 2.7 million |
| April 30, 2026 | 2.1 million | 1.3 million |
| Jan. 31, 2026 | 4.0 million | 1.9 million |
| Oct. 31, 2025 | 5.1 million | 717488 |
ALZN Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| July 31, 2026 | -1.1 million | 77199 |
| April 30, 2026 | -2.8 million | 623811 |
| Jan. 31, 2026 | -1.7 million | 9300 |
| Oct. 31, 2025 | -1.2 million | 31514 |
ALZN Net Income
No data available :(
ALZN Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| July 31, 2026 | 7.6 million | - | - |
| April 30, 2026 | 710689 | - | - |
| Jan. 31, 2026 | 2.7 million | - | - |
| Oct. 31, 2025 | 4.4 million | - | - |
ALZN Shares Outstanding
ALZN Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| July 31, 2026 | - | 1.1 million | 1.9 million | - |
| April 30, 2026 | - | 434006 | 2.4 million | -200000 |
| Jan. 31, 2026 | - | 1.3 million | 919025 | 50000 |
| Oct. 31, 2025 | - | 176283 | 821826 | - |
ALZN Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| July 31, 2026 | - | 27685 |
| April 30, 2026 | - | 27685 |
| Jan. 31, 2026 | - | 27685 |
| Oct. 31, 2025 | - | 27685 |
ALZN
Price: $1.34
52 week price:
Earnings Per Share: -2.03 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 216306
Market Capitalization: 5.2 million